argenx NV ADR (ARGX)vsMetaVia Inc. (MTVA)
ARGX
argenx NV ADR
$919.94
+5.82%
HEALTHCARE · Cap: $58.73B
MTVA
MetaVia Inc.
$1.58
-1.11%
HEALTHCARE · Cap: $7.64M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 71/100 (B).
ARGX
Strong Buy71
out of 100
Grade: B
MTVA
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+61.9%
Fair Value
$2191.36
Current Price
$919.94
$1271.42 discount
Intrinsic value data unavailable for MTVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 194.5x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : MTVA
The strongest argument for MTVA centers on Price/Book, Debt/Equity.
Bear Case : ARGX
The primary concerns for ARGX are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 41.7x leaves little room for execution misses.
Bear Case : MTVA
The primary concerns for MTVA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while MTVA is a value play — different risk/reward profiles.
MTVA carries more volatility with a beta of 0.97 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (71/100 vs 26/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
MetaVia Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
MetaVia Inc. is a forward-thinking technology firm specializing in transformative digital solutions that optimize connectivity and productivity across various sectors. By harnessing state-of-the-art artificial intelligence and cloud computing, MetaVia develops robust, customized platforms designed to address the unique challenges of its clientele. With a strong commitment to sustainability and social responsibility, the company not only meets current market expectations but also fosters long-term growth potential. Positioned strategically to capitalize on evolving trends in the tech industry, MetaVia aims to deliver substantial value to its shareholders while adapting to an ever-changing landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?